Who We Are
Oncoceptor is an early-stage privately-owned biotech company driven by passionate innovators, scientists, and clinicians. Founded by industry experts with deep expertise in oncology and immunotherapy, we are united by a shared vision: to make cancer a treatable and manageable condition.
Our Mission
At Oncoceptor, our mission is to unlock the potential of novel antigens to create the next generation of cancer immunotherapies. We are committed to transforming the landscape of cancer treatment by developing innovative, targeted therapies that offer new hope to patients worldwide.
Our Approach
We focus on the discovery and validation of novel antigens-unique markers on cancer cells that can be targeted by the immune system. By harnessing these antigens, we are developing personalized cell therapies that train the body’s immune system to recognize and destroy cancer cells with precision and efficiency. From early-stage discovery to clinical development, we are dedicated to advancing science that translates into real-world treatments for patients.
Explore
Leadership
Stefan Barisic, MD
(Founder & CEO)
Dr. Barisic is a physician-scientist with over 10 years of experience in cancer research. He was formerly a postdoctoral fellow at the National Institutes of Health in Bethesda, MD with Dr. Richard W. Childs. In this role, he spearheaded the development of novel antigen discovery platforms and engineered innovative cell therapies targeting cancer. Dr. Barisic and his colleagues were the first to develop a TCR-based therapy targeting an endogenous retroelement in kidney cancer – a groundbreaking milestone that reached clinical trial testing.
Stefan has an MD from the University of Belgrade School of Medicine (Serbia) and clinical training in internal medicine from Oregon Health & Science University (Portland, OR).
Let’s Talk